INTRODUCTION
MicroRNAs (miRNAs) belong to a novel class of small noncoding RNAs that repress gene expression by binding to the 3 0 untranslated regions (3 0 UTRs) of their target messenger RNAs (mRNAs). miRNAs have important roles in various biological processes, such as development, cell proliferation, differentiation and apoptosis. 1, 2 Accumulating evidence suggests that deregulation of miRNAs contributes to the development of diseases, including cancer. 3 The miRNA miR-125b is multi-faceted, with the ability to function as a tumor suppressor or an oncogene, depending on the cellular context. It is downregulated in malignancies originating in the ovary, bladder and breast [4] [5] [6] but is upregulated in leukemia, prostate cancer and glioma. [7] [8] [9] Interestingly, studies from mouse models reveal that ectopic expression of miR-125b in hematopoietic stem cells can induce leukemia 12-29 weeks post transplantation. Furthermore, miR-125b overexpression also accelerates the development of BCR-ABL-induced leukemia. 10 Most published studies have focused on analyzing the effect of miR-125b on cell proliferation. Overexpression of miR-125b promotes the proliferation of glial cells 7 but suppresses the proliferation of ovarian, bladder, breast and liver cancer cells. 6, [11] [12] [13] Regulators of proliferation, including BCL3, CDKN2A, E2F3, RAF1, ETS1, LIN28B2, ERBB3, ERBB2 and placenta growth factor 6, 7, [11] [12] [13] [14] [15] [16] have been identified as direct targets of miR-125b. It has been shown that overexpression of miR-125b inhibits apoptosis in glioma and prostate cancer cells, and miR-125b regulates the expression of pro-apoptotic proteins such as p53, Bak1, Puma and Bmf. [17] [18] [19] [20] To date, studies addressing the pro-apoptotic effect of miR-125b are limited 14, 21 and the detailed mechanisms remain unclear.
Hepatocellular carcinoma (HCC) is one of the most common cancers worldwide. It is characterized by resistance to anti-cancer therapy, progressive development, high postsurgical recurrence and extremely poor prognosis. Emerging evidence indicates that miR-125b has an important role in the development of HCC. miR125b is significantly downregulated in HCC 2, 14, 15, 22 and overexpression of miR-125b not only inhibits proliferation, anchorageindependent growth, migration and invasion in HCC cells but also represses tube formation of malignant hepatic endothelial cells. 14, 15 In a previous study, we observed that miR-125b overexpression induced spontaneous apoptosis in the HCC cell line PLC/PRF-5 and in a malignant hepatic endothelial cells.
14 However, the role of miR-125b in promoting apoptosis and the underlying mechanisms are still largely unknown. In this study, both gain-and loss-offunction analyses revealed that miR-125b not only induced spontaneous apoptosis in cancer cells but also sensitized cancer cells to various apoptotic stimuli, including nutrient deprivation and treatment with chemotherapeutic agents. A significantreduced rate of apoptosis was observed in HCC tissues. Moreover, we showed that Mcl-1, Bcl-w and interleukin (IL)-6R were direct targets of miR-125b, and they were involved in miR-125b-mediated apoptosis. In addition, we demonstrated that the mitochondrial pathway and caspase-3 were activated in miR125b-promoted apoptosis. Our results suggest that miR-125b may be an attractive target for cancer therapy.
RESULTS

Analysis on the function of miR-125b in apoptosis
To explore the effect of miR-125b in apoptosis, SMMC7721, HCT116 and 95D cell lines (derived from the liver, colorectal and lung cancers, respectively) were transfected with a miR-125b duplex or a negative control (NC). The morphological examination revealed that compared with the NC, miR-125b significantly increased spontaneous apoptosis in all three cell lines (Figure 1a) .
Rapid growth of malignancies results in insufficient blood supply, solid cancer cells thus should develop resistance to nutrient starvation-induced apoptosis. Therefore, we analyzed whether miR-125b could affect the apoptosis of cancer cells that were grown in nutrient-deprived medium. Twenty-four hours after transfection with NC or miR-125b, the cells were deprived of serum for different lengths of time. We observed that miR-125b expression significantly increased the sensitivity of different types of cancer cells to nutrient deprivation-stimulated apoptosis ( Figure 1b) .
Resistance to chemotherapeutic agents is another important characteristic of cancer cells. Thus, we determined whether miR-125b could enhance the chemosensitivity of tumor cells. Twenty-four hours after transfection with NC or miR-125b, the cells were treated with doxorubicin for various lengths of time. Compared with NC transfection, introduction of miR-125b obviously enhanced the apoptotic rates in all examined cell lines that were treated with doxorubicin ( Figure 1c) .
Next, the apoptosis-promoting effect of miR-125b from our above observation by morphological analysis was further confirmed by the use of terminal deoxynucleotidyl transferasemediated nick end labeling (TUNEL) staining (Supplementary Figure S1) . Moreover, activation of caspase-3 was also found in miR-125b-promoting apoptosis (Figures 1d and e) .
To verify the findings from the gain-of-function study, loss-offunction analysis was firstly performed in HCC cell line MHCC97L, which expressed higher levels of miR-125b among examined cell lines (Supplementary Figure S2 ). An inhibitor of miR-125b (antimiR-125b), which obviously decreased the level of endogenous miR-125b (Supplementary Figure S3) , was transfected into MHCC97L. In response to either serum deprivation or doxorubicin treatment, anti-miR-125b-transfected cells displayed significantly reduced rates of apoptosis, compared with the control, anti-miR-C transfectants (Figures 2a and b) . Similarly, miR-125b inhibition also attenuated both nutrient deprivation and chemotherapeutic agent-induced apoptosis in another two hepatoma cell lines, SMMC7721 and SK-HEP-1 (Figures 2c and d) .
To confirm the association of miR-125b with apoptosis in vivo, we further evaluated the miR-125b level and the apoptotic rate in human HCC specimens using quantitative PCR and TUNEL staining, respectively. Compared with adjacent non-tumor tissues, miR-125b was significantly downregulated in HCC tissues (Supplementary Figure S4A) . Linear regression analysis disclosed a significant positive correlation between the level of miR-125b and the percentage of TUNEL-positive cells in HCC tissues (Figure 3, Supplementary Figure S4B ), suggesting that miR-125b downregulation may lead to decreased apoptosis in HCC cells.
Taken together, these results indicate that miR-125b promotes apoptosis in our cell models and deregulation of miR-125b may confer cellular resistance to nutrient starvation and chemotherapyinduced apoptosis.
Characterization of direct target genes of miR-125b We next explored the molecular mechanisms responsible for the apoptosis-promoting effect of miR-125b. First, the potential target genes that may mediate the effect of miR-125b were chosen for experimental validation, based on bioinformatic prediction and the known function of the genes in apoptosis regulation. Predicted target genes of miR-125b were retrieved from the TargetScan database. We then focused our attention on Mcl-1, Bcl-w and IL-6R, because Mcl-1 and Bcl-w are anti-apoptotic members of the Bcl-2 family and are frequently overexpressed in tumor tissues; 23, 24 IL-6R is the binding subunit specific to IL-6, and the binding of IL-6 to IL-6R activates the Janus kinase/signal transducer and activator of transcription (Stat)3 pathway and in turn induces the expression of genes involved in apoptosis and cell cycle regulation. 25 A dual-luciferase reporter system was first used to evaluate whether Mcl-1, Bcl-w and IL-6R were direct target genes of miR125b. The wild-type or mutant 3 0 -UTR fragments of these genes (Supplementary Figure S5) were cloned downstream of the firefly luciferase reporter gene. We found that co-transfection of miR125b significantly suppressed the activity of firefly luciferase that carried the wild-type but not mutant 3 0 UTR of Mcl-1, Bcl-w or IL-6R (Figure 4a ), indicating that miR-125b may suppress gene expression through its binding sequences at the 3 0 UTR of target genes.
Subsequently, the effect of miR-125b on cellular endogenous expression of its potential target genes was examined. Figure S8) . Moreover, the apoptosis-promoting effect of triple-knockdown of Mcl-1, Bcl-w and siIL-6R was greater than that of any one individual silencing Twenty-four hours after transfection, SMMC7721 cells were deprived of serum (d) or treated with 0.2 mg/ml doxorubicin (e) for 24 h, followed by detection of pro-and active caspase-3 using western blotting. b-Actin, internal control. * indicates a nonspecific band. For (a-c), apoptosis was analyzed by 4 0 -6 0 -diamidino-2-phenylindole staining. RNAiMAX, cells were exposed to transfection mixture that contained Lipofectamine RNAiMAX but not the RNA oligoribonucleotide. **Po0.01; ***Po0.001.
miR-125b promotes apoptosis J Gong et al ( Figure 5e ) but similar to that of miR-125b expression (Figure 1b) . These results suggest that miR-125b may promote apoptosis by targeting Mcl-1, Bcl-w and IL-6R.
As Mcl-1, Bcl-w and Bcl-xL belong to the Bcl-2 family, which has crucial roles in the mitochondrial apoptosis pathway, we next evaluated whether overexpression of miR-125b disrupted the mitochondria membrane potential (DCm) by double staining with MitoTracker Deep Red FM (MTRed) and MitoTracker Green FM (MTGreen). The intensity of MTRed staining depends on DCm, whereas the intensity of MTGreen remains the same regardless of DCm and was thus used as an internal staining control. As shown, loss of DCm was distinctly increased in the miR-125b transfectants compared with the control group (15.7% versus 7.8%, Figures 6a and b) . The results suggest that miR-125b may promote apoptosis by suppressing the anti-apoptotic molecules of Bcl-2 family and in turn activating the mitochondrial apoptotic pathway.
Taken together, our findings suggest that miR-125b not only directly represses the endogenous expression of Mcl-1 and Bcl-w, but also indirectly reduces the levels of Mcl-1 and Bcl-xL by attenuating IL-6/Stat3 signaling, which result in activation of the mitochondrial pathway and in turn induction of apoptosis (Figure 6c ).
DISCUSSION
Although abnormal miR-125b expression is frequently observed in various types of cancers, the biological outcome of miR-125b deregulation is largely cellular context-dependent. [4] [5] [6] [7] 9, 10 To date, the role of miR-125b in the regulation of apoptosis remains unclear. Here, we found frequent downregulation of miR-125b in HCC tissues, as well as a significant correlation between a reduced miR-125b level and a decreased rate of apoptosis. We also showed that restoration of miR-125b significantly increases apoptosis in the liver, colorectal and lung cancer cell lines in the absence of apoptotic stimuli and upon nutrient starvation or chemotherapeutic drug exposure. Our results highlight the importance of miR-125b deregulation in cancer development and the possibility of miR-125b as a new target for anti-cancer therapy. miR-125b is a multi-faceted molecule that may promote or inhibit apoptosis, depending on cellular context. The opposite effects mediated by miR-125b in different types of cells may provide a basis for targeted therapy, if the underlying mechanisms are disclosed.
Apoptosis serves as a natural barrier to cancer formation and development. Tumor cells must evolve a variety of strategies to circumvent apoptosis so that they can escape clearance by immune surveillance systems or anti-cancer therapy and survive in the harsh tumor microenvironment, where hypoxia and nutrient deprivation are common. 26 Multiple mechanisms are used by tumor cells to evade apoptosis, such as the functional loss of the p53 tumor suppressor, increased expression of anti-apoptotic regulators (Bcl-2, Bcl-xL, Mcl-1 and Bcl-w) and survival signals (insulin-like growth factor 1/2), downregulation of proapoptotic factors (Bax, Bak1, Bim and Puma) and short-circuiting of the extrinsic ligand-induced death pathway. The Bcl-2 family, which consists of both pro-and anti-apoptotic proteins, regulates the permeability of the mitochondrial membrane. Mcl-1, Bcl-xL and Bcl-w, the anti-apoptotic members of the Bcl-2 family, suppress apoptosis largely through binding to pro-apoptotic proteins (Bax and Bak1) that are embedded in the mitochondrial outer 0 -6 0 -diamidino-2-phenylindole staining. RNAiMAX, the cells were exposed to transfection mixture that contained Lipofectamine RNAiMAX but not the RNA oligoribonucleotide. *Po0.05; **Po0.01 and ***Po0.001. Figure 3 . miR-125b expression is positively correlated with the level of apoptosis in HCC tissues. The level of mature miR-125b was examined by real-time qPCR and normalized to RNU6B expression. Apoptosis was determined using TUNEL staining. The correlation between the miR-125b level and the rate of apoptosis in HCC tissues was analyzed using Spearman's correlation coefficient. The median level of miR-125b in all examined samples was set to 1.
miR-125b promotes apoptosis J Gong et al membrane and preserve the integrity of mitochondria. Mcl-1, Bcl-xL and Bcl-w are frequently upregulated in various types of cancer 23, 24, 27 and function as essential pro-survival molecules in tumor progression. We show that miR-125b directly suppresses Mcl-1 and Bcl-w and indirectly represses Bcl-xL by targeting IL-6R. Knockdown of Mcl-1, Bcl-w and IL-6R closely mimics the apoptosis-promoting effect of miR-125b expression, and activation of the mitochondrial and caspase-3 pathways is involved in miR-125b-promoted apoptosis. These results clearly indicate that Mcl-1, Bcl-w and IL-6R are the predominant mediators of miR-125b-induced apoptosis in liver cancer cells, although other unidentified targets may also be involved.
The reason why miR-125b can exert both apoptosis-promoting and inhibiting function is still unclear. It has been reported that miR-125b suppresses apoptosis by negatively regulating p53, Bak1, Puma and Bmf in leukemia, glioma and prostate cancer cells. [17] [18] [19] [20] However, neither the level of p53 mRNA nor the Bak1 protein in HCC cell lines is altered by miR-125b expression. 14, 15 In our HCC cell model, no obvious change was found in the protein level of p53 after either overexpression or suppression of miR-125b (Supplementary Figure S9) . We speculate that the following mechanisms may be responsible for the opposite role of miR-125b in different cells. First, the relative concentration of target mRNAs in different cell types may decide which set of targets will be regulated by miR-125b. Second, cell-type-specific competitive mRNAs or UTR-binding cofactors may affect the binding of miR-125b to its target sites. For example, the pseudogene PTENP1 could compete with PTEN for miRNA binding, thereby attenuating the repression of miRNAs on PTEN. 28 Third, the location of miRNA target genes may affect the repressive effect of miRNA. For instance, the repression of CAT-1 by miR-122 is relieved by the relocation of CAT-1 mRNA from cytoplasmic processing bodies to polysomes under the cellular stress. 29 Collectively, the regulatory effect of miRNA may be more dynamic than previously anticipated. Much more extensive studies are needed to understand the mechanisms that contribute to the diverse roles of miR-125b.
IL-6 is a multifunctional cytokine that has pleiotropic roles in immune regulation, inflammation, liver regeneration and tumorigenesis. Serum IL-6 levels are elevated in patients with hepatitis, miR-125b promotes apoptosis J Gong et al cirrhosis and HCC. 30 IL-6 signals through IL-6R/gp130 and activates Janus kinases, which then phosphorylate several substrates to induce signaling through the Stat3, mitogen-activated protein kinase and phosphatidylinositol 3-kinase pathways. Among them, the Stat3 pathway is the main one activated by IL-6 because most effects of IL-6 can be abolished by disrupting Stat3 signaling. 31 IL-6/Stat3 signaling pathway is found to be over-activated in various types of human malignancies. 25 It has been reported that Stat3 is a target of miR-125b in myeloid cells. 32 However, enforced expression of miR-125b has minimal effects on the expression of Stat3 in our cell models. Alternatively, we found that miR-125b could suppress the phosphorylation of Stat3 and in turn the expression of its target genes, such as Mcl-1 and Bcl-xL. Furthermore, restoration of miR-125b decreased the level of all Mcl-1, Bcl-xL and Bcl-w, whereas IL-6 treatment and knockdown of IL-6 or IL-6R only affected the expression of Mcl-1 and Bcl-xL, but had no effect on Bcl-w level. Therefore, miR-125b may promote apoptosis via several different mechanisms, that is, direct suppression of Mcl-1 and Bcl-w expression by binding to their Twenty-four hours after transfection with the indicated single siRNA (50 nM) or siRNA mixture (16.7 nM of each siMcl-1, siBcl-w and siIL-6R), SMMC7721 cells were deprived of serum for 72 h and then subjected to DAPI staining. **Po0.01; ***Po0.001.
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Membrane-bound IL-6R is mainly expressed on hepatocytes and immune cells, 25 which may explain why IL-6R is undetectable in HCT116 and 95D, cell lines that originate from colorectal and lung cancers. Except when expressed on the cell membrane, IL-6R exists as a soluble form (sIL-6R) in serum and other biologic fluids. sIL-6R is generated by alternative splicing or by proteolytic cleavage from the membrane-bound IL-6R. IL-6 can also bind to sIL-6R and form an IL-6/sIL-6R complex, which then associates with gp130, the ubiquitously expressed IL-6-signal transducer. This ternary complex can transduce the IL-6 signal into cells in the absence of membrane-bound IL-6R. 25 Notably, sIL-6R levels are elevated in sera from HCC patients. 30 Therefore, downregulation of miR-125b may not only enhance IL-6 signaling in hepatic cells but may also affect other cells by increasing the level of sIL-6R.
In summary, we investigated the potential role of miR-125b in apoptosis and the mechanisms underlying its actions. Our data suggest that downregulation of miR-125b may favor malignant transformation and tumor progression, and implicate potential application for miR-125b in anti-cancer therapy.
MATERIALS AND METHODS Reagents
The reagents used were as follows: rabbit polyclonal antibodies 
Tissue specimens and cell lines
A total of 32 paired HCC and adjacent nontumor liver tissues were collected from patients who underwent surgical resection at the Department of Hepatobiliary Oncology at Cancer Center, Sun Yat-sen University in Guangzhou, PR China. The non-tumor tissues were collected at least 2-cm distant from the tumor border. Both tumor and non-tumor tissues were histologically confirmed. All patients were unrelated ethnic Han Chinese who lived in Southeast China. None of the patients had received local or systemic anticancer treatment before the operation. This study was approved by the Institute Research Ethics Committee at the Cancer Center. Informed consent was obtained from each patient.
Cell lines derived from the human HCC (MHCC97L, SMMC7721), liver adenocarcinoma (SK-HEP-1), colorectal (HCT116) and lung (95D) cancers were maintained in Dulbecco's modified Eagle's medium (Hyclone, Logan, UT, USA) supplemented with 10% fetal bovine serum (Hyclone, Thermo Fisher Scientific, Victoria, Australia).
RNA oligoribonucleotides and plasmids
All RNA oligoribonucleotides were purchased from Genepharma (Shanghai, PR China). The miRNA duplexes corresponding to mature miR-125b were designed as described previously. 33 The siRNAs targeting mRNA of human Mcl-1 (GenBank accession no. NM_021960), Bcl-w (NM_004050), IL-6R (NM_000565, NM_181359) or IL-6 (NM_000600.3) were denoted as siMcl-1, siBcl-w, siIL-6R and siIL-6, respectively. The NC RNA duplex for both the miR125b mimic and the siRNA was nonhomologous to any human genome sequences. The miR-125b inhibitor (anti-miR-125b) with a sequence complementary to the mature miR-125b and its control (anti-miR-C) were 2 0 -O-methyl-modified RNA oligoribonucleotides. The bioinformatic analysis predicted one miR-125b-binding site in Mcl-1 and Bcl-w and two binding sites in IL-6R (Supplementary Figure S5) . A wildtype 3 0 UTR segment of human Mcl-1 (492 bp) or IL-6R (484 and 589 bp for two sites, respectively) mRNA that contained putative binding site for miR125b was PCR-amplified and inserted into the EcoRI/XbaI sites downstream of the stop codon of firefly luciferase in pGL3cm vector, which was created based upon the pGL3-control vector (Promega, Madison, WI, USA), as miR-125b promotes apoptosis J Gong et al described previously. 34 A wild-type 3 0 UTR segment (668 bp) of human Bcl-w mRNA was inserted into the EcoRI/ApaI sites of pGL3cm. The mutant 3 0 UTR (Supplementary Figure S5) , which contained the mutated sequence in the complementary site for the seed region of miR-125b, was generated using fusion PCR based on the construct with wild-type 3 0 UTR. All RNA oligoribonucleotides and the primers are listed in Supplementary Table S1 .
Cell transfection RNA oligoribonucleotides were reversely transfected using Lipofectamine RNAiMAX (Invitrogen, Carlsbad, CA, USA). A final concentration of 50 nM RNA duplex or 200 nM miRNA inhibitor was used for each transfection, unless otherwise indicated. The RNA transfection efficiency using this method is B70-80%, 34 and the overexpression of miRNA mimics persists for at least 4 days. 35 Co-transfection of the RNA duplex and plasmid DNA was conducted using Lipofectamine 2000 (Invitrogen). All transfections were performed according to the manufacturer's protocol.
Apoptosis analysis
Apoptosis was detected by morphological examination and TUNEL assay. For morphological examination, cells were stained with 4 0 -6 0 -diamidino-2-phenylindole and those with condensed or fragmented nuclei were considered to be apoptotic cells. At least 500 cells were counted for each sample. TUNEL staining was conducted using the In situ Cell Death Detection Kit (Roche, Penzberg, Germany), according to the manufacturer's protocol. At least 750 cells were counted for each sample.
Luciferase reporter assay SMMC7721 cells plated in a 48-well plate were co-transfected with 10 nM RNA duplex, 2 ng pRL-TK (Promega) and 10 ng firefly luciferase reporter containing the wild-type or mutant 3 0 UTR of the indicated target gene. pRL-TK, which expresses Renilla luciferase, was co-transfected as an internal control to correct for differences in both transfection and harvest efficiency. Transfections were performed in duplicate and repeated in at least three independent experiments. Luciferase activity was detected as described. 34 Analysis of gene expression miRNA level was evaluated by quantitative real-time PCR, mRNA level by semiquantitative RT-PCR and protein expression by western blotting. Among the 32 pairs of HCC and matched adjacent liver tissues, miR-125b expression has been previously reported in 19 of these samples. 14 
Analysis of DCm
Cells were stained with both MitoTracker Deep Red FM and MitoTracker Green FM (Invitrogen) at 37 1C for 20 min in the dark and washed with Ca 2 þ -free phosphate-buffered saline, followed by flow cytometry analysis (Gallios, Beckman Coulter, Fullerton, CA, USA).
Immunofluorescent staining for p-Stat3
Cells were cultured on coverslips, fixed with methanol and stained with monoclonal antibodies against p-Stat3 (sc-8059, Santa Cruz Biotechnology), followed by incubation with Alexa Fluor 488-conjugated goat antimouse immunoglobulin G (Molecular Probes, Carlsbad, CA, USA) and nuclear counterstaining with 4 0 -6 0 -diamidino-2-phenylindole. Fluorescent images were examined and photographed with a Zeiss Axio Imager Z1 (Zeiss, Jena, Germany).
Statistical analysis
Data were expressed as the mean±s.e.m. from at least three independent experiments. The Student's t-test was applied to compare the differences between two groups. Correlation between the miR-125b level and the apoptotic rate in HCC tissues was analyzed using Spearman's correlation coefficient. A P-value of o0.05 was used as the criterion of statistical significance, and all statistical tests were two-sided.
